Bayhill Therapeutics, Inc. Announces Presentation of MS Drug Candidate BHT-3009 at American Academy of Neurology 60th Annual Meeting
Published: Apr 11, 2008
PALO ALTO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA™ platform to develop novel and targeted autoimmune disease treatment candidates, today announced that the Company’s co-founder and Vice President of Research, Hideki Garren, M.D., Ph.D., will present at the American Academy of Neurology 60th Annual Meeting (AAN) in Chicago. Dr. Garren’s podium presentation will discuss Bayhill’s lead product candidate BHT-3009 in relation to an abstract (#857) entitled “Results from a Phase 2 Trial of a Myelin Basic Protein Encoding DNA Vaccine for Relapsing Multiple Sclerosis" at session S22: “Multiple Sclerosis: Clinical Trials III” on Wednesday, April 16 at 2:30 PM central time at McCormick Place West Convention Center, Chicago, IL.